{"id":5072,"date":"2017-08-22T12:17:11","date_gmt":"2017-08-22T11:17:11","guid":{"rendered":"http:\/\/backup.altanalaw.com\/?p=5072"},"modified":"2017-08-22T12:28:23","modified_gmt":"2017-08-22T11:28:23","slug":"altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales","status":"publish","type":"post","link":"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales","title":{"rendered":"Altana Advises Onxeo in the Divestment of Two Non-Core Oral Pathology Products to Vectans Pharma"},"content":{"rendered":"

Paris, 22 August 2017<\/p>\n

Altana advised Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology laboratory specializing in the development of innovative drugs for the treatment of orphan diseases, in the divestment of two historic products: Sitavig\u00ae (labial herpes) and Loramyc\u00ae (oropharyngeal candidiasis), to Vectans Pharma, a private laboratory \u00a0that develops and commercializes drugs for oral pathologies.<\/p>\n

Sitavig\u00ae and Loramyc\u00ae are the first two products developed and registered in Europe and the US by Onxeo\u2019s R&D teams. They are currently licensed to several international distributors or are awaiting market authorization in several key countries.<\/p>\n

Onxeo divested to Vectans Pharma all assets relating to the two products (notably patents, regulatory authorizations and outstanding contracts) for an upfront payment of \u20ac4 million. The agreement also contains a provision for a potential earn-out payment based on the cumulated worldwide commercial performance of the products. Onxeo will also receive, from its existing partners, most of the expected milestone payments related to predefined regulatory or commercial performance benchmarks.<\/p>\n

This operation demonstrates the strategic transformation initiated a few years ago by Onxeo in its aim to become a worldwide leader and pioneer in the rare and orphan cancer sector.<\/p>\n

 <\/p>\n

Counsel Onxeo<\/strong><\/p>\n

Altana: Jean-Nicolas Soret (Partner), Fabien Pouchot (Counsel) and Vincent Guilaine (Associate).<\/p>\n

Counsel Vectan Pharma<\/strong><\/p>\n

Almain: Edgard Nguyen (Partner).<\/p>\n

 <\/p>\n

About Altana<\/strong><\/p>\n

Altana is an independent Paris-based business law firm of 80 lawyers with multi-disciplinary teams offering a combination of transactional and litigation expertise in the following areas:<\/p>\n

Arbitration\/Mediation, Competition\/Distribution, Construction & Real Estate Law, Corporate\/M&A, Criminal Law, Employment, Insurance, Intellectual and Digital Property , Litigation, Public Economic Law and Restructuring.<\/p>\n

All 80 lawyers, including 22 partners, share the common values of entrepreneurial spirit, independence, commitment, international perspective, lasting and privileged client relations, effective involvement by the partners in each case, pragmatic and innovative solutions.<\/p>\n

 <\/p>\n

Press Contacts<\/strong><\/p>\n\n\n\n
Avocom<\/strong><\/p>\n

Virginie Jubault<\/p>\n

v.jubault@avocom.fr<\/p>\n

+33 (0)1 48 24 00 41<\/td>\n

 <\/p>\n

Nathalie Merle<\/p>\n

n.merle@avocom.fr<\/p>\n

+33 (0)1 48 24 00 39<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/strong><\/p>","protected":false},"excerpt":{"rendered":"

Paris, 22 August 2017 Altana advised Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology laboratory specializing in the development of innovative drugs for the treatment of orphan diseases, in the divestment of two historic products: Sitavig\u00ae (labial herpes) and Loramyc\u00ae (oropharyngeal candidiasis), to Vectans Pharma, a private laboratory \u00a0that develops and commercializes drugs for […]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5072","post","type-post","status-publish","format-standard","hentry","category-medias","expertise-droit-societes-fusions-acquisitions","avocat-fabien-pouchot","avocat-jean-nicolas-soret"],"yoast_head":"\nAltana Advises Onxeo in the Divestment of Two Non-Core Oral Pathology Products to Vectans Pharma - Advant Altana<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"[:fr]Altana conseille Onxeo dans la cession \u00e0 Vectans Pharma de deux produits non strat\u00e9giques dans les pathologies buccales [:en]Altana Advises Onxeo in the Divestment of Two Non-Core Oral Pathology Products to Vectans Pharma[:] - Advant Altana\" \/>\n<meta property=\"og:description\" content=\"Paris, 22 August 2017 Altana advised Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology laboratory specializing in the development of innovative drugs for the treatment of orphan diseases, in the divestment of two historic products: Sitavig\u00ae (labial herpes) and Loramyc\u00ae (oropharyngeal candidiasis), to Vectans Pharma, a private laboratory \u00a0that develops and commercializes drugs for […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales\" \/>\n<meta property=\"og:site_name\" content=\"Advant Altana\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-22T11:17:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-08-22T11:28:23+00:00\" \/>\n<meta name=\"author\" content=\"Altana Communication\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Altana Communication\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales\",\"url\":\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales\",\"name\":\"[:fr]Altana conseille Onxeo dans la cession \u00e0 Vectans Pharma de deux produits non strat\u00e9giques dans les pathologies buccales [:en]Altana Advises Onxeo in the Divestment of Two Non-Core Oral Pathology Products to Vectans Pharma[:] - Advant Altana\",\"isPartOf\":{\"@id\":\"https:\/\/backup.altanalaw.com\/#website\"},\"datePublished\":\"2017-08-22T11:17:11+00:00\",\"dateModified\":\"2017-08-22T11:28:23+00:00\",\"author\":{\"@id\":\"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/backup.altanalaw.com\/#website\",\"url\":\"https:\/\/backup.altanalaw.com\/\",\"name\":\"Advant Altana\",\"description\":\"Soci\u00e9t\u00e9 d'avocats \u00e0 la Cour de Paris\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/backup.altanalaw.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6\",\"name\":\"Altana Communication\",\"url\":\"https:\/\/backup.altanalaw.com\/en\/author\/altanacomm\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"[:fr]Altana conseille Onxeo dans la cession \u00e0 Vectans Pharma de deux produits non strat\u00e9giques dans les pathologies buccales [:en]Altana Advises Onxeo in the Divestment of Two Non-Core Oral Pathology Products to Vectans Pharma[:] - Advant Altana","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"[:fr]Altana conseille Onxeo dans la cession \u00e0 Vectans Pharma de deux produits non strat\u00e9giques dans les pathologies buccales [:en]Altana Advises Onxeo in the Divestment of Two Non-Core Oral Pathology Products to Vectans Pharma[:] - Advant Altana","og_description":"Paris, 22 August 2017 Altana advised Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology laboratory specializing in the development of innovative drugs for the treatment of orphan diseases, in the divestment of two historic products: Sitavig\u00ae (labial herpes) and Loramyc\u00ae (oropharyngeal candidiasis), to Vectans Pharma, a private laboratory \u00a0that develops and commercializes drugs for […]","og_url":"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales","og_site_name":"Advant Altana","article_published_time":"2017-08-22T11:17:11+00:00","article_modified_time":"2017-08-22T11:28:23+00:00","author":"Altana Communication","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Altana Communication","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales","url":"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales","name":"[:fr]Altana conseille Onxeo dans la cession \u00e0 Vectans Pharma de deux produits non strat\u00e9giques dans les pathologies buccales [:en]Altana Advises Onxeo in the Divestment of Two Non-Core Oral Pathology Products to Vectans Pharma[:] - Advant Altana","isPartOf":{"@id":"https:\/\/backup.altanalaw.com\/#website"},"datePublished":"2017-08-22T11:17:11+00:00","dateModified":"2017-08-22T11:28:23+00:00","author":{"@id":"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-la-cession-a-vectans-pharma-de-deux-produits-non-strategiques-dans-les-pathologies-buccales"]}]},{"@type":"WebSite","@id":"https:\/\/backup.altanalaw.com\/#website","url":"https:\/\/backup.altanalaw.com\/","name":"Advant Altana","description":"Soci\u00e9t\u00e9 d'avocats \u00e0 la Cour de Paris","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/backup.altanalaw.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6","name":"Altana Communication","url":"https:\/\/backup.altanalaw.com\/en\/author\/altanacomm"}]}},"_links":{"self":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts\/5072"}],"collection":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/comments?post=5072"}],"version-history":[{"count":7,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts\/5072\/revisions"}],"predecessor-version":[{"id":5082,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts\/5072\/revisions\/5082"}],"wp:attachment":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/media?parent=5072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/categories?post=5072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/tags?post=5072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}